SF Journal of Clinical Pharmacology and Research

ABOUT JOURNAL

SF Clinical Pharmacology and Research focuses on research concerning the effects, safety, efficacy, and clinical application of medicines and therapeutic agents. The journal provides a platform for pharmacologists, clinicians, pharmacists, researchers, and healthcare professionals investigating how drugs interact with biological systems and how pharmacological knowledge can improve patient treatment.

The journal covers areas including clinical pharmacology, pharmacokinetics, pharmacodynamics, drug interactions, adverse drug reactions, therapeutic drug monitoring, pharmacogenomics, drug safety, medication use, clinical trials, rational pharmacotherapy, drug metabolism, individualized treatment, and translational research connecting pharmacological discoveries with clinical applications.

The journal welcomes original research, review articles, systematic reviews, clinical studies, pharmacological investigations, drug safety studies, methodological contributions, brief reports, and other scientifically valuable manuscripts relevant to clinical pharmacology. The journal seeks to promote responsible and evidence-based use of medicines and support research that improves therapeutic effectiveness, safety, and patient care.

FEATURED ARTICLES

Review Article

Gout and Rheumatoid Arthritis: Available Options for Pharmacotherapy. Overview of World Data

Wisniewski D and Uzar I^*

Due to adverse effects, old-age uricosuric medications have been withdrawn only to assisted treatment of gout. Their place was taken by Xanthine Oxidase (XOI) inhibitors as the first-choice medication. Although they are easier to monitor and free from many side effects, they have a limited spectrum of associations. New-generation uricosuric medications have been included in combination therapy with XOI. They can also be used alone in the case of patients with XOI

PDF HTML

Letter to Editor

Is it Possible to Prevent Covid-19 by ACE Inhibitors?

Bozorgnia A, Gharibzadeh S and Bozorgnia M^*

Outbreaks of emerging infectious diseases continue to challenge human health. The reported incidence of emerging and re-emerging zoonotic disease is increasing in many parts of the world [1]. In December of 2019, a novel coronavirus (SARS-CoV-2) crossed species barriers to infect humans [2] and was effectively transmitted from person to person, leading to a pneumonia outbreak first reported in Wuhan, China [3-5]. This virus causes coronavirus disease-19 (COVID-19) with

PDF HTML

Review Article

Health Benefits of Plant-Derived Bioactive Secondary Metabolites as Dietary Constituents

Aryadeep Roychoudhury^* and Rituparna Bhowmik

Plants are one of the most important sources of human nutrition and they also act as store house of important pharmaceuticals. Plant-derived bioactive compounds have long been used to treat diseases in traditional medicine. Plant biotechnology provides a blooming opportunity for improving the bioactive compounds in our food. This coupled with the emergence of concepts like nutritional therapy and phytotherapy makes us curious about understanding the health benefits of the bioactive compounds in our food.

PDF HTML

View All Articles →

JOURNAL SCOPE

Scope

Covers clinical pharmacology, drug efficacy and safety, pharmacokinetics, therapeutic monitoring, drug interactions, pharmacogenomics, and rational medicine use.

Research Areas

Clinical Pharmacology Pharmacology Clinical Drug Research Therapeutics Drug Development Drug Discovery Pharmacokinetics Pharmacodynamics Pharmacogenomics Pharmacogenetics

EDITORIAL BOARD

Abdul Rouf

University of Florida

USA

Brahma N.Singh

CSIR-National Botanical Research Institute

India

Chandra sekhar Devulapalli

Norwegian Labour and Welfare Administration

Norway

Genzhu Wang

Beijing Electric Power Hospital

China

Saeid Abbasi-Maleki

Islamic Azad University

Iran

Zhi-Ling YU

Hong Kong Baptist University

China